Besides NSCLC, several previous studies showed that increased expression level of CXCL5 was an adverse prognosis biomarker in pancreatic cancer, hepatocellular carcinoma, and bladder cancer.38, 39, 40. This evidence concerns the gene CXCL5 and non-small cell lung carcinoma.